Clinical Trials on Platelet-aggregation Inhibitors

Total 2047 results

CTI BioPharma

Completed

Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post- Essential Thrombocythemia Myelofibrosis Previously Treated With Ruxolitinib

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post- Essential Thrombocythemia Myelofibrosis

United States, Spain, United Kingdom, Hungary, Korea, Republic of, France, Italy, Sweden
Baylor College of Medicine
Shire

Active, not recruiting

Low VW Activity in Adolescent HMB (Low VWF)

Von Willebrand Factor Deficiency

United States
NS Pharma, Inc.

Completed

Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States
Baxalta now part of Shire

Completed

Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Complex in Type 3 Von Willebrand Disease

Von Willebrand Disease

United States, Germany, United Kingdom, Italy, Austria, Canada
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
Sierra Oncology, Inc.

Completed

Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Primary Myelofibrosis | Post-Polycythemia Vera | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada
Sierra Oncology, Inc.

Completed

Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Weill Medical College of Cornell University
Genentech, Inc.

Withdrawn

A Trial to Treat Patients With ITP Who Do Not Achieve a Durable Response to Rituxan Alone

Idiopathic Thrombocytopenic Purpura (ITP)

United States
National Institute of Blood and Marrow Transplant...
Novartis

Unknown

Association of FcγRIIIA Polymorphism and THPO Expression With Response to Eltrombopag in Refractory ITP Patients

Immune Thrombocytopenic Purpura (ITP)

Pakistan
Instituto Grifols, S.A.

Completed

Clinical Trial in Patients Diagnosed With Immune Thrombocytopenic Purpura (ITP)

Immune (Idiopathic) Thrombocytopenic Purpura

Spain, Russian Federation, United Kingdom
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Safety and Efficacy Study of Hetrombopag Olamine in Chronic Idiopathic Thrombocytopenic Purpura (ITP) Patients

Chronic Idiopathic Thrombocytopenic Purpura

China
Peking University People's Hospital

Unknown

Observation Study of Prednisone and Cyclosporine in Treatment of Thrombocytopenia in Hepatitis B Cirrhosis

Hepatitis B | Thrombocytopenia | Cirrhosis
Universidad del Azuay

Completed

Study on Von Willebrand Disease and Hemophilia in Cuenca, Ecuador (VWD)

Hemophilia A | Hemophilia B | Von Willebrand Disease

Ecuador
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
GlaxoSmithKline

Completed

Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

Japan
Archemix Corp.

Terminated

Clinical Outcome Study of ARC1779 Injection in Patients With Thrombotic Microangiopathy

Thrombotic Thrombocytopenic Purpura | Thrombotic Microangiopathy

United States, Italy, Austria, Canada, United Kingdom
University Hospital, Bordeaux

Not yet recruiting

Molecular Analysis of Thrombocytopenia and Cancer (MATAC): Investigating Antigenic Mimicry Between Platelets and Tumor Cells in Patients With Immune Thrombocytopenia (ITP) Associated With Cancer (MATAC)

Neoplasms | Cancer | Immune Thrombocytopenia | Immune Thrombocytopenic Purpura

France
University Hospital, Angers

Recruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes (PHEMOP)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

France
Assiut University
Association for Training, Education, and Research in Hematology, Immunology...

Not yet recruiting

Thrombopoietin Agonists in Patients With Idiopathic Thrombocytopenic Purpura

ITP - Immune Thrombocytopenia
Novartis Pharmaceuticals

Recruiting

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

Primary Immune Thrombocytopenia (ITP)

Spain, Italy, France, Germany, China, Korea, Republic of, Czechia, Turkey, Malaysia, United States, Argentina, Australia, United Kingdom, Poland
Bloodworks
Ergomed; Octapharma; Mary M. Gooley Hemophilia Center

Recruiting

Von Willebrand Factor in Pregnancy (VIP) Study (VIP)

Von Willebrand Diseases

United States
Mount Sinai Hospital, Canada

Active, not recruiting

Venous Thromboembolism in Hematologic Malignancy and Hematopoietic Cell Transplant Patients: a Retrospective Study

Thrombocytopenia | Hematologic Malignancy | Venous Thromboembolic Disease | Thrombosis, Venous | Bleeding Hemorrhage

Canada
Institute of Hematology & Blood Diseases Hospital...
Xijing Hospital; Xi'an Central Hospital; The Second Hospital of Hebei Medical... and other collaborators

Active, not recruiting

A Randomized Trial Comparing Optimized rhTPO Treatment With Eltrombopag Treatment in Pre-treated ITP Pts (TE-ITP)

Previously Treated Primary Immune Thrombocytopenia

China
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Hutchison Medipharma Limited

Active, not recruiting

Phase III Study on HMPL-523 for Treatment of ITP

Primary Immune Thrombocytopenia (ITP)

China
University Hospital, Toulouse

Completed

Risk Factors for Thrombosis in Immune Thrombocytopenia (RiFT-ITP)

Immune Thrombocytopenia

France
Baxalta now part of Shire

Completed

Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjects With Chronic Idiopathic Thrombocytopenic Purpura

Immune Thrombocytopenic Purpura (ITP)

Poland, Hungary, Germany, Czechia
Leiden University Medical Center
Sanquin-LUMC J.J van Rood Center for Clinical Transfusion Research

Unknown

Neurodevelopmental Outcome After Fetal Neonatal AlloImmune Thrombocytopenia (NOFNAIT)

Neurodevelopmental Abnormality | Fetal and Neonatal Alloimmune Thrombocytopenia | Long Term Adverse Effects | Intravenous Immunoglobulin Adverse Reaction

Netherlands
Institute of Hematology & Blood Diseases Hospital
Henan Cancer Hospital; Nantong University; Tianjin Medical University Second... and other collaborators

Unknown

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)

China
Fundación Grupo de Investigación en Cuidados Intensivos...
Alexion Pharmaceuticals

Unknown

Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series

Pregnancy | Atypical Hemolytic Uremic Syndrome

Colombia
Nantes University Hospital

Completed

Study Assessing an Algorithm-based Strategy of Eculizumab Discontinuation in Children and Adults With aHUS (STOPECU)

Atypical Hemolytic Uremic Syndrome

France
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
Seoul National University Hospital
Hallym University Medical Center

Unknown

H. Pylori Eradication for Moderate ITP

Immune Thrombocytopenia | Immune Thrombocytopenic Purpura | Helicobacter Pylori

Korea, Republic of
Eisai Inc.

Completed

Study of AKR-501 Tablets Taken Orally Once Daily for 28 Days in Patients With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura | Purpura, Thrombocytopenic, Idiopathic

United States
Alexion Pharmaceuticals

Terminated

aHUS Observational Long Term Follow-Up (LTFU)

Atypical Hemolytic Uremic Syndrome

France, Canada, United States, Belgium, Italy, United Kingdom, Netherlands, Australia, Austria, Germany, Sweden, Switzerland
National Heart, Lung, and Blood Institute (NHLBI)

Completed

Drug Etiology of Aplastic Anemia and Related Dyscrasias

Purpura, Thrombocytopenic | Agranulocytosis | Anemia, Aplastic | Blood Disease
Bio Products Laboratory

Completed

A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)

Chronic Idiopathic Thrombocytopenic Purpura

United States, India, Argentina
Eisai Inc.

Completed

Pharmacokinetic and Pharmacodynamic Study in Healthy Subjects Comparing the Interactions Between E5501 and Verapamil and Cyclosporine.

Idiopathic Thrombocytopenic Purpura (ITP)

United States
Hospital Universitari Vall d'Hebron Research Institute
Hospital Universitario La Paz

Not yet recruiting

Identification and Characterization of Genetic Variants in Hereditary Angioedema (GENOMAEH_01)

Hereditary Angioedema With C1 Esterase Inhibitor Deficiency

Spain
University Hospital, Caen

Completed

Tyrosine Kinase Inhibitor Withdrawal Syndrome in CML Patients: Observatory Trial Studying the Biological Factors. (KIWIS)

Chronic Myeloid Leukemia | Withdrawal Syndrome | Tyrosine Kinase Inhibitor

France
University of Colorado, Denver
National Heart, Lung, and Blood Institute (NHLBI)

Not yet recruiting

Optimizing Pulsatility During Cardiopulmonary Bypass to Reduce Acute Kidney Injury

Thrombocytopenia | Surgery | Acute Kidney Injury | Hemolysis

United States
University Hospital, Lille

Not yet recruiting

Severe Congenital Hemostatic Defects, Cerebral MIcrobleeds and COGnition (HEMICOG)

Cerebral Microbleeds, Congenital Haemophilia, Congenital Von Willebrand Disease
Bleeding and Clotting Disorders Institute Peoria...
Genentech, Inc.

Recruiting

Emicizumab for Severe Von Willebrand Disease (VWD) and VWD/Hemophilia A (BCDI-XII)

Von Willebrand Disease, Type 3 | Concomitant VWD and Hemophilia

United States
Peking University People's Hospital

Recruiting

The Combination of Sitagliptin and Danazol as the Treatment of Steroid-resistant/Relapse Immune Thrombocytopenia

Blood Coagulation Disorders | Thrombocytopenia | Immune Thrombocytopenia | Physiological Effects of Drugs

China
University Hospital, Lille

Recruiting

Frequency of Hemorrhages Associated With the Functional Anomalies of Willebrand Factor in Emergency Patients (WITECMO-H)

Von Willebrand Diseases

France
Alexion
Syneos Health

Recruiting

Atypical Hemolytic-Uremic Syndrome (aHUS) Registry

Atypical Hemolytic-Uremic Syndrome

France, Germany, Israel, Italy, United Kingdom, Canada, United States, Australia, Belgium, Denmark, Korea, Republic of, Poland, Russian Federation, Spain, Taiwan
Incyte Corporation

Active, not recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

Primary Myelofibrosis | Myelofibrosis | Post Essential Thrombocythemia Myelofibrosis | Post Polycythemia Vera Myelofibrosis

United States, Spain, United Kingdom, Korea, Republic of, Belgium, France, Israel, China, Japan, Italy, Germany, Taiwan, Poland, Austria, Finland, Hungary, Norway, Romania, Turkey
AO GENERIUM

Completed

Comparative Study of Clinical Efficacy and Safety of GNR-069 and Nplate in Patients With ITP

Idiopathic Thrombocytopenic Purpura

Russian Federation
Sierra Oncology, Inc.

Completed

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Simplify 1)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Germany, Spain, Israel, Bulgaria, Romania, Japan, Taiwan, Korea, Republic of, Australia, Belgium, Canada, Netherlands, Singapore, Poland, Hungary, Denmark, Sweden, United Kingdom, Czechia, Austria

Clinical Trials on Platelet-aggregation Inhibitors

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations